Ernexa Therapeutics (ERNAW) EBT (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of EBT data on file, last reported at -$5.5 million in Q1 2026.

• Quarterly EBT rose 32.32% year-over-year to -$5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.5 million (down 649.84% YoY) and the FY2025 annual result came in at -$14.1 million, down 70745.0% from the prior year.
• EBT fell to -$5.5 million in Q1 2026, from -$1.6 million in the prior quarter.
• In the past five years, EBT ranged from a high of $38.8 million in Q4 2024 to a low of -$26.6 million in Q3 2024.
• A 5-year average of -$2.4 million and a median of -$5.5 million in 2024 frame the typical range for EBT.
• The widest YoY moves for EBT: up 729.87% in 2024, down 374.94% in 2024.
• Tracing ERNAW's EBT over 5 years: stood at $20.1 million in 2022, then tumbled by 130.69% to -$6.2 million in 2023, then soared by 729.87% to $38.8 million in 2024, then sank by 104.03% to -$1.6 million in 2025, then slumped by 254.6% to -$5.5 million in 2026.
• The last three EBT figures came in at -$5.5 million (Q1 2026), -$1.6 million (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.